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had “symptoms” as a primary endpoint; a drug for rheumatoid arthritis (RA) had 
“functioning” as its lead secondary endpoint; the remaining six drugs (for pulmo-
nary arterial hypertension (PAH), Crohn’s Disease, smoking cessation, Myasthenia 
Gravis, asthma, and overactive bladder) had “HRQOL”, “symptoms, and “functioning” 
as minor secondary endpoints. Three drugs -indicated for PAH, seizure, and RA- had 
PRO claims in their labels. ConClusions: Although not yet prominent in Japan, 
PROs are used in drug clinical trials and label claims. Symptoms, Quality of Life, and 
Functioning are the most common PROs used.
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objeCtives: Interest in delivering Patient Reported Outcome Measures (PROMs) 
using mobile devices (e-PROMs) has increased in recent years. However there is 
debate about the level of equivalence between the traditional pencil and paper 
and electronic modes of administration. The aim of this study is to compare the 
equivalence of delivering a widely used generic PROM (EQ-5D-5L) pencil and paper 
and mobile phone administration modes. Methods: A mobile version of the 
EQ-5D-5L was developed with guidance from the EuroQol Group. Two hundred 
respondents from a research cohort of people in South Yorkshire were identified, 
and randomly allocated to one of the administration modes based on stratifications 
for age and gender (and across a range of self-reported health issues). The EQ-5D-5L 
was completed either using a mobile device or the standard paper version which 
were sent out to the respondent. Follow up usability questions were also included. 
EQ-5D equivalence was compared at the dimension and utility and VAS score level 
using ANOVA. Results: Response rates were comparable across the arms, with 
the majority of respondents owning a smartphone. The mean EQ-5D-5L utility and 
VAS scores and the frequency of respondents endorsing the individual EQ-5D-5L 
categories across each of the dimensions does not differ across the administration 
modes. The majority of the mobile phone completion sample agreed that the mobile 
version of EQ-5D-5L was easy to complete, and that the phone was easy to use, and 
that they would complete e-PROMs again. ConClusions: Completing e-PROMs 
using mobile phones produces equivalent results and response rates to pencil and 
paper methods, and respondents are positive towards completing questionnaires 
using these methods. This provides evidence that e-PROMs are valid for use to 
collect data in a range of settings including clinical trials, routine care, and as, for 
example, health diaries.
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objeCtives: Increasingly, patients become active participants in making decisions 
on their therapy. A survey was conducted to understand the experience and expecta-
tions of patient organizations (POs) with patient reported outcomes (PRO) as they 
are measured today. Methods: An online survey was conducted in English lan-
guage throughout May 2014 among 40 participants at a global cross disease patient 
forum to prepare a discussion of the relevance and usefulness of patient reported 
outcomes from the patient perspective. The participants represented a broad range 
of disease specific and disease independent patient organizations from various 
countries including USA, European countries, Asia, Latina America, Middle East 
and Australia. Results: Current PROs were perceived as useful but not optimal 
for informing patients in making their own therapy decisions. All of 9 typical PRO 
domains were considered important (between 3.9 and 4.7 on a 5 point scale) with 
the most important being symptoms (4.6±0.89), Physical Function (4.65±0.59) and 
psychological well-being (4.7±0.47). The participants thought that PROs should be 
part of all studies throughout the entire life cycle of products including evidence 
for clinical research, reimbursement decisions, listing decisions, health technology 
assessment (HTA) or comparative effectiveness (CER) studies (all between 4.25 and 
4.6 on a 5-point scale). Increasingly, POs develop their own instruments to elicit 
PROs from the patient perspective and as patient based evidence. ConClusions: 
The concept of patient reported outcomes is good in principle but more is needed 
for integrating additional aspects which are relevant for the patients themselves 
to understand the full impact and consequences of the therapy. Patient reported 
outcomes are a key endpoints from the patient perspective and should be elicited 
throughout the entire development and marketing cycle of products.
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objeCtives: To migrate the UK English Endometriosis Health Profile (EHP) from 
paper to ePRO format for completion by respondents on a touchscreen tablet device. 
Following migration, to produce translations of the UK English ePRO version in 
25 languages. Methods: The draft ePRO version of the EHP was reviewed by the 
questionnaire developer, the translation project manager and the sponsor. During 
the initial review the questionnaire was assessed for linguistic equivalence with 
the paper version and for usability in relation to the target patient group. A number 
of factors were considered including layout, response input method and forced 
completion. Decisions were made based on the recommendations of the developer, 
translation vendor and ePRO vendor according to the specialism of each party, tak-
ing into consideration the capabilities of the software and the requirements of the 
cific terms, such as “discouraged” and “angered,” translate with greater conceptual 
equivalency. Therefore, when seeking to measure the various concepts associated 
with the term “frustrated,” measuring more specific constructs independently using 
separate questionnaire items is recommended.
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objeCtives: To demonstrate the increasing use of mobile phones to collect patient 
reported outcomes in research as a valid method of data collection. Methods: A 
literature search was conducted looking at articles published between 2009 and 2014 
that referenced electronic diaries of some description. Articles were pulled out that 
specifically referenced mobile or cellular phones. Results: 39 of out of 191 articles 
found specifically referenced mobile. The studies referenced were carried out on 
populations with an age range of 8 years up to 80 (mean 35.4; SD 16.6) and were split 
into 15 therapy areas including metabolic and genetic disorders, pain, weight man-
agement, sexual activity, respiratory, multiple sclerosis and gastroesophageal reflux 
disease. Population size ranged from 12 to 994 (mean 208.3; SD 269.2), and subjects 
reported for a minimum of 7 days (up to 6 reports per day) to a maximum of 2 years 
(mean 154.3 days; SD 170.6). Notably, 18 out of the 39 studies allowed the subjects 
to use their own mobile phone for the reporting and 19 articles referenced smart-
phones specifically. ConClusions: All concluded that mobile phones were suited 
to collect data from subjects. It was noted that the use of mobiles was acceptable 
as they are used them in everyday life and found to be convenient; the technology 
was also inexpensive to implement. The fact that 46.2% of the studies allowed the 
subjects to use their own mobile phones for the reporting emphasises the practical-
ity of using mobile phones in patient reported outcomes. Although the mean age of 
all the studies was relatively low, the age range was very wide and researchers can 
be confident that older populations could use mobile phones to collect these data. 
The technical evolution of mobile technologies and ubiquitous nature show that 
this technology is a valid means to collect patient reported outcomes.
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objeCtives: According to the Federal, Food, Drug and Cosmetic Act (FD&C Act), 
prescription drug promotion must not be false or misleading, have fair balance, be 
consistent with the approved product labeling, and only include claims substanti-
ated by adequate and well-controlled clinical studies. The Office of Prescription 
Drug Promotion (OPDP), formerly the Division of Drug Marketing, Advertising and 
Communications (DDMAC), was set up to protect the public health by assuring pre-
scription drug information is truthful, balanced and accurately communicated. 
The objective of this study was to review the DDMAC/OPDP warning and notice of 
violations letters to find out 1) how many violations were in relation to PRO and 
HRQL claims and 2) how those evolved after the publication of the FDA PRO draft 
guidance in 2006. Methods: DDMAC letters were identified on the “Enforcement 
Activities by FDA” webpage. Letters from 1998 to 2013 were all reviewed manually 
to identify violations in relation to PRO and HRQL claims during the periods before 
and after the publication of the guidance (1998-2005 vs. 2006-2013). Results: 763 
letters were reviewed. Each letter included information about one or more viola-
tions of the FD&C Act, such as “Omission of Risk Information”, “Overstatement of 
Efficacy”, “Unsubstantiated Superiority Claims”, etc. The review showed a letter 
volume on the decline (n= 524 for 1998-2005, n= 239 for 2006-2013), with an increase 
in PRO violations: 19.50% of all letters (1998-2005) vs. 30.5% (2006-2013). HRQL vio-
lations were rarer after 2006 and were more often detected as implicit: 20 false 
HRQL claims, of which two were considered implicit (1998-2005) vs. seven false 
HRQL claims, of which four were considered implicit (2006-2013). Examples will be 
presented. ConClusions: The FDA guidance on PRO measure seems to have had 
an influence on HRQL information: less ads with explicit violations and a OPDP’s 
tendency to argue over implicit claims.
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objeCtives: The use of patient-reported outcomes (PROs) in label claims in the 
US and Europe is regulated by the US FDA and the EMA, respectively. Japan’s 
Pharmaceuticals and Medical Devices Agency (PMDA) does not have such regu-
lations. This study was done to determine whether Japan-based pharmaceutical 
companies utilize PRO endpoints at all and in what way, by investigating their 
inclusion of PROs in pharmaceutical clinical trials and drug information materi-
als. Methods: We searched the websites of ClinicalTrials. gov and the PMDA for 
information on 14 drugs which had received PRO claim approvals from both the 
US FDA and EMA from 2006-2010. Search terms were the generic and/or brand 
names of the selected drugs (in English and Japanese, as appropriate). PROs were 
classified as “symptoms”, “functioning”, and “HRQOL” based on the PRO scale used. 
A table comparing PRO type, endpoint positioning, and US and Europe-approved 
label claims versus the PRO information reported in Japan for the same drug was 
created. Results: Of the above fourteen drugs, four are not yet available in Japan. 
One drug with an FDA and EMA-approved “symptoms” claim did not have such in 
its Japan clinical trial. Of the nine remaining drugs, the PRO endpoints were as fol-
lows: two drugs, indicated for epileptic seizure and for benign prostatic hyperplasia, 
